96 Results

People

  1. Morris
    Morris
  2. Scher
    Scher
  3. Slovin
    Slovin
  4. Osborne
    Osborne
  5. Sadelain
    Sadelain
  6. Larson
    Larson
  7. Lewis
    Lewis
  8. O'Donoghue
    O'Donoghue
  9. Pandit-Taskar
    Pandit-Taskar
  10. Reuter
    Reuter

Groups

  1. Department of Medicine (49)
  2. Solid Tumor Oncology Division (37)
  3. Genitourinary Oncology Service (36)
  4. GSK Faculty (31)
  5. Radiology, Department of (28)
  6. Molecular Pharmacology and Chemistry Program Faculty (25)
  7. Sloan Kettering Institute Faculty (25)
  8. Hematologic Malignancies, Division of (24)
  9. Molecular Imaging and Therapy Service (22)
  10. Sloan Kettering Institute Postdocs (21)
  1. "prostate specific membrane antigen"
Formats
  1. Journal Article (78)
  2. Review (12)
  3. Editorial (3)
  4. Correspondence (2)
  5. Miscellaneous (1)
Groups
  1. Department of Medicine (49)
  2. Solid Tumor Oncology Division (37)
  3. Genitourinary Oncology Service (36)
  4. GSK Faculty (31)
  5. Radiology, Department of (28)
  6. Molecular Pharmacology and Chemistry Program Faculty (25)

More Groups

People
  1. Michael Morris (15)
  2. Howard Scher (12)
  3. Michel Sadelain (9)
  4. Steven Larson (9)
  5. Susan Slovin (9)
  6. Joseph Osborne (7)

More People

Years
  1. 2025 (5)
  2. 2024 (13)
  3. 2023 (11)
  4. 2022 (4)
  5. 2020 (5)
  6. 2019 (3)

More Years

Publications
  1. Journal of Nuclear Medicine (10)
  2. European Urology (6)
  3. Journal of Urology (5)
  4. Clinical Cancer Research (4)
  5. Cancer (3)
  6. European Journal of Nuclear Medicine and Molecular Imaging (3)

More Publications

Publishers
  1. Elsevier Science, Inc. (15)
  2. Elsevier Inc. (13)
  3. Springer (11)
  4. Society of Nuclear Medicine (10)
  5. American Association for Cancer Research (8)
  6. Wiley Blackwell (5)

More Publishers

Results (96)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)
    Journal Article

    Ballangrud, A. M.; Yang, W. H.; Charlton, D. E.; McDevitt, M. R.; Hamacher, K. A.; Panageas, K. S.; Ma, D.; Bander, N. H.; Scheinberg, D. A.; Sgouros, G.
    Cancer Research (2001)

    Fulltext@MSK | Save
  • The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer
    Journal Article

    Kelly, W. K.; Osman, I.; Reuter, V. E.; Curley, T.; Heston, W. D. W.; Nanus, D. M.; Scher, H. I.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Identification and characterization of circulating prostate carcinoma cells
    Journal Article

    Wang, Z. P.; Eisenberger, M. A.; Carducci, M. A.; Partin, A. W.; Scher, H. I.; Ts'o, P. O. P.
    Cancer (2000)

    Fulltext@MSK | Save
  • Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues
    Journal Article

    Chang, S. S.; Reuter, V. E.; Heston, W. D. W.; Hutchinson, B.; Grauer, L. S.; Gaudin, P. B.
    Cancer (2000)

    Fulltext@MSK | Save
  • Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
    Journal Article

    Gong, M. C.; Chang, S. S.; Sadelain, M.; Bander, N. H.; Heston, W. D. W.
    Cancer and Metastasis Reviews (1999)

    Fulltext@MSK | Save
  • Bedeutung des prostataspezifischen membranantigens (PSMA): Eine neurocarboxypeptidase und membran-folat-hydrolase
    Journal Article

    Heston, W. D. W.
    Der Urologe A (1996)

    Fulltext@MSK | Save